Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib as second-line treatment for advanced non-small cell lung cancer (real-world, observational)
ChiCTR2000034455Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival (PFS). Planned start Jul 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000034455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034455.